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ACUTE AND CHRONIC REJECTION: COMPARTMENTALIZATION AND
KINETICS OF COUNTERBALANCING SIGNALS IN CARDIAC TRANSPLANTS
ANUPURNA MAHARAJ KRISHEN KAUL
ABSTRACT
Heart disease is the major cause of mortality in the United States and other parts of the
world. Heart transplantation is the treatment of choice for patients with end stage heart
failure. However, transplanted organs fail due to either acute or chronic rejection. This
acute and chronic rejection impacts distinct compartments of cardiac allografts. Acute
rejection is characterized by infiltration of mononuclear cells whereas chronic rejection is
characterized

by

progressive

narrowing

of

coronary

arteries.

In

a

minor

histoincompatibility mismatch mouse model we found hearts transplanted from male to
female C57BL/6 mice undergo an acute rejection with diffuse interstitial infiltrates at 2
weeks that resolve by 6 weeks when about half of the large arteries develop CAV. These
processes are dependent on T cells because no infiltrate developed in T cell deficient
mice. Markers of M1 macrophages were upregulated in the interstitium acutely and then
decreased as markers of M2 macrophages increased chronically. Interstitial and arterial
infiltrates were microdissected and expression of an array of 86 genes was screened by
real time PCR. Programmed cell death protein 1 (PD1), a negative costimulator, and its
ligand PDL1 were highly upregulated in the interstitium during the resolution of acute
rejection. Flow cytometry analysis of graft infiltrating cells confirmed an enrichment of
macrophages expressing PDL1. Treatment with a blocking antibody to PDL1 in the acute
phase increased interstitial T cell infiltrates. In the arterial compartment, Toll Like

ix

Receptor 4 (TLR4) was upregulated at 6 weeks. Hyaluronan, an endogenous ligand of
TLR4, was increased in arteries with neointimal expansion. Injection of hyaluronan
fragments increased intragraft production of chemokines. Our data indicate that negative
co-stimulatory pathways are critical for the resolution of acute interstitial infiltrates. In
the arterial compartment recognition of endogenous ligands including hyaluronan by
innate TLR4 may support the progression of cardiac allograft vasculopathy (CAV).
Importantly, our model localizes many of the molecular markers that have been
associated with acute and chronic rejection in clinical studies of cardiac transplants.
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CHAPTER I
INTRODUCTION

1.1 Introduction to transplant

1.1.1 Overvie w and brief history.

The history of transplantation is long and complex. The idea of replacing diseased
or damaged body parts has been around for millennia. Transplants of normal tissues and
organs have been studied since the early 1900’s. George Shone in 1912 demonstrated
that skin grafted between genetically disparate animals (termed “homografts” in that era)
were rejected. Moreover, he also demonstrated that subsequent grafts from the same
donor were rejected more rapidly than the first. This so-called “second-set” reaction was
the first evidence of the immune basis of rejection of normal tissues. In 1914, James B.
Murphy demonstrated that resistance to tumor homografts was dependent on the
lymphoid system. Also by the end of 1920s, scientists at the Rockefeller Institute
established other principles of transplantation immunology including the central role of
the lymphocyte

1

. However, widespread appreciation of the immune basis of

1

transplantation was established by the careful observations of Peter Medawar that were
instigated by the need to perform skin grafts on injured pilots in World War II 2 . After the
war Peter Medawar conducted extensive studies of skin homografts in rabbits, more
firmly characterizing the timing, histological morphology, and immunological nature of
rejection. It was Peter Medawar’s experiments that demonstrated induction of chimerism
can prevent graft rejection. In 1957, Morton Simonsen discovered GVHD (graft versus
host disease) in chickens that he had injected as embryos with allogeneic lymphoid cells.
He also demonstrated that to cause GVHD, lymphocytes must be mobile which suggested
cellular immunity is important 3 . Better evidence of cellular immunity was provided by
Avrion Mitchison. Mitchison introduced the method of passive transfer of cells and
serum to study transplantation immunity using tumors 4 . In 1959, James Gowans gave
proof of lymphocyte mobility by showing lymphocytes recirculate from blood to lymph
and back again. Billingham, Brent and Medawar 5, 6 applied passive transfer methods to
study skin grafts in mice. These passive transfer studies demonstrated that cells from the
lymph nodes of a transplant recipient could transfer a second-set response to a previously
“naïve” animal.
During this same period there were sporadic reports of organ transplants. With
the exception of a few autografts of kidneys in dogs, all of these transplants resulted in
failure.

The first successful kidney transplant in humans was performed between

genetically identical twin brothers by Murray and colleagues in 1954

7, 8

.

Kidney

transplants between genetically disparate individuals had poor survival until effective
immunosuppressive drugs were discovered. Joan Main and Richmond Prehn showed that
weakening the immune system of adult mice by radiation allows them to induce

2

chimerism by inoculating bone marrow cells. Skin grafts were then accepted if they came
from the bone marrow donor strain 9 . It was not until 1963 when Starzl reported the
combination of prednisone with azathioprine that clinically acceptable success was
attained 10 .
With the subsequent introduction of better immunosuppressive drugs, particularly
cyclosporine in 1980, transplants of liver, hearts and other organs began to have
successful outcomes 11 .
In the developed countries the transplantation of human tissue and organ has
become common. The commonly transplanted vascularized solid organs are: kidney,
liver, heart and lung. The less frequently transplanted solid organs are pancreas and
intestine.

More recently composite tissue transplants have been performed.

These

include arms or hands as well as the highly publicized face transplants. Among nonvascularized solid organ transplant are heart valve and cornea. Pancreatic islets are
injected but not surgically grafted. Bone marrow and pluripotent stem cell transplants are
also transplanted as cell infusions, but because of their immune competence, have the
additional risk of causing graft versus host disease. The success of a transplant differs
with the tissue or organ transplanted 12 .

1.2 Heart Transplant:
1.2.1

Overvie w and brief history:

Heart transplant is the current therapy for end stage heart failure. The technique for
heart transplantation was developed at Stanford University by Norman Shumway. The

3

first human heart transplant was performed by Christiaan Barnard in South Africa in
December 1967. This was followed by a rush of transplants around the world. However,
the limitation of this procedure was survival rates which were measured in days or weeks.
This low survival rate was because of rejection and opportunistic infections. The surgical
technique has changed little. In 1970s the use of endomyocardial biopsy helped clinicians
to confirm diagnosis of acute allograft rejection. In 1980, cyclosporine was introduced,
which resulted in improved survivals

13-14

. Advances in immnosuppressive drugs have

resulted in continued improvements in graft survival.

1.2.2

Statistics/ Survival of heart transplant patients.

There are currently over 2900 people with end stage heart disease waiting for a heart
transplant in the United States. The median graft survival is approximately 10 years.
According to the 2013 Registry for the international society for heart and lung
transplantation (ISHLT) “Acute rejection accounts for no more than 11% of deaths’’
because of advances in immunosuppressive drugs which have curtailed the acute
rejection to a great extent

15

. However, chronic rejection, which occurs months to years

after transplantation, still remains a major challenge for the heart transplant patients.
The most common indications for cardiac transplantation in the adult are coronary heart
disease and nonischemic cardiomyopathies. In children cardiomyopathy and congenital
heart disease are the two most common indications for transplantation 16 .

4

1.3.

Overvie w of cardiac allograft re jection.

Solid organ transplant rejection occurs because of the recipient’s immune response to
donor tissue

17

. At present, success of heart transplantation has mostly been achieved

through better understanding of the immunology of transplant rejection and the
application of various strategies for recognizing, treating, and preventing allograft
rejection 18 .
Cardiac allograft rejection can be classified into three categories: hyperacute, acute and
chronic rejection 19-20 .

1.3.1 Types of allograft rejection

Hype racute rejection is characterized by thrombotic occlusion of the graft vasculature
that occurs within few minutes after the transplant. This hyperacute rejection results from
pre-formed donor specific antibodies (DSA) to ABO blood group antigens or the so
called major histocompatibility antigens (named HLA in humans for Human Leukocyte
Antigens)

21

. The pathogenesis of hyperacute rejection involves antibody- mediated

activation of the complement cascade which produces severe damage to the endothelial
cells, as well as platelet activation followed by coagulation of blood and thrombosis

16

.

Antibodies to HLA are formed generally through pregnancy, blood transfusions or
previous transplantation

22

. Cross-matching involves placing recipient serum potentially

containing donor-specific HLA antibodies onto donor lymphocytes containing HLA
antigens. Antibody reactivity can be assessed either by cytotoxic reaction or with

5

fluorescently labeled reagents

23

. With the help of blood typing for ABO compatibility

and cross- matching for antibodies to HLA prior to transplant, hyperacute rejection has
virtually been eliminated.

Acute Rejection occurs most frequently weeks to months after transplantation and it can
involve both cell and antibody mediated rejection. Acute rejection is characterized by an
intense infiltration of T cells and macrophages in the myocardium or antibodies binding
to microvasculature, that if untreated results in graft loss within days to weeks 24 .

Chronic Rejection occurs months to years after transplant and is characterized by the
progressive narrowing of the coronary artery 25-26 . This narrowing of the coronary artery
is called cardiac allograft vasculopathy (CAV)

24, 26

. Chronic rejection results from cell

mediated or antibody mediated rejection.

1.3.2

Incidence and Pathology of acute cardiac allograft re jection.

The use of immunosuppressive drugs has curtailed acute rejection to a great extent.
However, still 20% to 50% of patients may experience acute cardiac allograft rejection at
least once within one year post transplant 27 .
Currently endomyocardial biopsies (EMB) are used as a diagnostic tool for acute cardiac
allograft rejection

28

. Biopsy of myocardium can detect lymphocytic infiltration or

complement deposition and macrophage infiltration which are characteristic of acute
cellular or antibody mediated rejection, respectively.

6

A detailed grading system

(International Society of Heart and Lung Transplantation or ISHLT guidelines) is used to
assess the severity of cellular and antibody mediated rejection and guide treatment

29

.

Based on the grading system that was originally adopted by the ISHLT in 1990, the
revised 2004 working formulation for the standardization of nomenclature in the
diagnosis of heart rejection classified acute cardiac allograft rejection into three grades
(0R to 3R, with 3R being the most severe) (Figure 1A-1R). Briefly, the revised categories
of cellular rejection are as follows: Grade 0R represents no rejection. Grade 1R represents
mild rejection, and shows presence of immune cell infiltrates in the interstitial and/or
perivascular space, with up to 1 focus of myocyte damage. Grade 2R, or moderate
rejection, is characterized by the presence of two or more foci of cellular infiltrate with
associated myocyte damage. In grade 3R represents severe rejection which is
characterized by diffuse cellular infiltrate along with multifocal myocyte damage
including hemorrhage, edema or vasculitis 29 .
In severe cases like grade 3R there is also participation of granulocytes in the
rejection process

16

. In acute cardiac allograft rejection both donor and recipient-derived

antigen presenting cells are involved and they can trigger direct and indirect alloresponse,
respectively. In direct allorecognition, the intact foreign donor MHC antigens and
peptides presented on the surface of donor APCs are recognized by recipient T cells. The
donor organ-derived APCs can migrate from the allograft to the recipient’s lymphoid
tissues, where they activate, through the direct pathway, CD4+ and CD8+ T cells

30-31

.

On the other hand, in indirect allorecognition, the recipient APCs first take up and
process the donor MHC antigens, before presenting the donor-derived allopeptides to
recipient T cells. While both direct and indirect pathways are activated as part of the

7

alloimmune response post-transplant, it is thought that the direct pathway is primarily
responsible for initiating the acute cellular rejection process, whereas the indirect
pathway has been linked more so to the development of CAV and chronic rejection 30-31 .

Figure 1 (A-F). Grades of cellular Rejection: Hematoxylin-eosin stain on frozen
section of (A) showing Grade 0R with intact myocardim with no infiltrates, (B) showing
Grade 0R with no infiltrates in interstitium or perivascular space, (C-F) showing Grade
1R with mild interstitial infiltrates in between myocytes (Tan et al 2007).

8

Figure 1 (G-L). Grades of cellular Rejection: Hematoxylin-eosin stain on frozen
section of (G-H) showing Grade 1R with focal diffused interstitial infiltrates of
mononuclear cells, (I-J) showing Grade 1R with focal myocyte damage, (K-L) showing
grade 2R with mltifocal myocyte damage and intense interstitial infiltrates (Tan et al
2007).

9

Figure 1 (M-R). Grades of cellular Rejection: Hematoxylin-eosin stain on frozen
section of (M-N) showing Grade 2R with moderate rejection and widening of the
interstitium, (O-Q) showing Grade 3R with diffuse inflammation. Myocardial pieces are
diffusely infiltrated by dense mononuclear inflammatory infiltrates, (R) showing Grade
3R with edema and hemorrhage with mixed inflammatory infiltrates including neutrophil
(Tan et al 2007).

10

1.3.3

Incidence and Pathology of Chronic cardiac allograft rejection.

Chronic rejection occurs months to years after transplantation and can also be the
result of antibody- and cellular-mediated components. Immunosuppression has curtailed
acute rejection, however chronic rejection still remains a challenge for heart transplant
patients. Recent estimates indicate that allograft vasculopathy is experienced by 32% of
patients within five years after transplantation, and by 53% of patients within ten years of
transplantation 32 . The mortality rate among patients with transplant vasculopathy is high,
and diagnosis of allograft vasculopathy is complicated. Chronic rejection is characterized
by the progressive concentric narrowing of the coronary artery (Figure 2A-B) along the
length of coronary vessels 25 . This narrowing of coronary artery is called CAV 24, 26 . Early
stages may cause eccentric and focal stenosis that are more obvious in arteries. This loss
in lumen results from intimal expansion (Figure 3) which occurs due to infiltration of
host T cells and macrophages and smooth muscle cell proliferation 33-34 . CAV is a major
factor that limits long term survival after cardiac transplantation.
Examination of endomyocardial biopsies is the current standard for diagnosing
rejection. However, it does not detect changes in the coronary arteries which are the site
of chronic rejection. Therefore, cardiac allograft vasculopathy is detected clinically by
radiological techniques. There are studies that use more sensitive method of diagnosis
like intravascular ultrasound (IVUS). IVUS detected new arteriopathy in about half of
cardiac transplants within one year after transplantation 35 . Within 10 years of transplant,
approximately 90% of patients develop significant CAV 35 .

11

Both immune and nonimmune factors contribute to CAV development and impact
graft survival. Endothelial cells express major histocompatibility complex class I and
class II antigens, and thus are primary targets of cell- mediated and humoral immune
responses

16, 36-38

. Activated T cells secrete cytokines like tumor necrosis factor,

interleukins and interferon which promote proliferation of alloreactive T cells that in turn
activate monocytes and macrophages, and stimulate expression of adhesion molecules by
endothelial cells

39

. After macrophages are activated they are recruited to the intima

where they release cytokines and growth factors, leading to smooth muscle cell
proliferation and synthesis of extracellular matrix

40

. The humoral immune response

contributes to CAV through antibody production against HLA and endothelial cell
antigens. Endothelial cell dysfunction resulting from sustained inflammatory injury also
predisposes to thrombosis, vasoconstriction, and vascular smooth muscle proliferation 40 .
Nonimmune factors are thought to influence CAV mainly by modulating adaptive
immune responses

41

. Some of the nonimmune factors that are associated with the

development and progression of CAV include arteritis

42-43

, myocardial ischemia, donor-

transmitted coronary atherosclerosis, cytomegalovirus status, deficient fibrinolysis and
immunosuppressive therapy 26 .
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Figure 2. Schematic representation of a coronary artery, site of CAV (A) H& E staining
of human heart tissue showing pathology of cardiac allograft vasculopathy (B).

Figure 3. Schematic representation of vascular remodeling in CAV depicts mechanisms
by which vascular remodeling can impact the vessel lumen. Intimal hyperplasia occurs
13

through the recruitment of inflammatory cells and smooth muscle like cells and extension
of extracellular matrix reduces luminal diameter. Adventitial fibrosis restricts positive
remodeling of medial smooth muscle cells. Increased medial tone can also participate in
intimal responses by increasing wall shear stresses (Mitchell et al 2009).

1.3.4

Small Animal Models of Cardiac Allografts.

In small animals, orthotopic cardiac transplantation is not technically feasible.
Consequently, smaller animal models involve either heterotopic cardiac transplantation or
vascular grafting. These approaches are complementary models for CAV.
In our laboratory, we are using heterotopic cardiac transplantation model (Figure
4). Abdominal heterotopic cardiac transplantation is the gold standard for studying
cardiac allograft rejection; it is a primarily vascularized model. Graft beating is routinely
used to assess ongoing graft function. CAV lesions develop within 6–12 weeks and
accurately replicate most aspects of human disease, including histology and cellular
composition

44-45

. Isografts serve as controls: they do not develop CAV lesions and

almost no T cells and macrophages infiltrate the graft. This is because isografts have no
genetic incompatibilities with the recipient and therefore do not elicit an alloimmune
response. CAV may occur if there is perioperative ischemic injury 46 . These isografts are
used as controls to allograft.

There are certain limitations to the rodent heterotopic transplant model. The first
and foremost is heterogeneity of CAV severity within a given allograft necessitating
larger numbers of allografts to obtain meaningful data. Secondly, unlike human coronary

14

arteries that have extensive epicardial segments, the murine coronary circulation is
predominantly intramyocardial and could be more influenced by mediators present in
adjacent areas of myocardial rejection. In addition, the rodent coronary diameters are also
substantially smaller than their human counterparts and have a less well- developed
media. Also in comparison to human vessels, murine endothelium does not constitutively
express MHC II and is relatively resistant to neointimal lipid deposition and
atherosclerosis.
In an orthotopic location, transplanted hearts have physiologic patterns of
lymphatic drainage with associated lymph nodes, where antigen presentation and
lymphocyte activation can occur. Although from heterotopic transplants vascular
trafficking to the spleen likely occurs, it is unclear where the analogous antigen
presentation takes place and whether it is comparable to the human situation 26 .

15

Figure 4. Schematic describing the heterotopic cardiac transplantation procedure.
Cardiac allografts are primarily vascularized and beat but are not hemodynamically
loaded; the host does not rely on the transplant to survive. The donor aorta is
anastomosed to the host abdominal aorta, and the donor pulmonary vein is sewn to the
host inferior vena cava. The aortic valve is initially competent and the coronary arteries
and myocardium are perfused at aortic pressures; blood returns to the right atrium and
into the host inferior vena cava (Mitchell et al 2009).

1.4 Mechanisms controlling cardiac allograft re jection.

1.4.1 Role of Co-stimulatory molecules.

T cells play an important role in acute and chronic cardiac allograft rejection

47-48

.

Therefore, interfering with T cell activation offers the potential of prolonging graft
survival through modulation of the alloresponse. The process of T cell activation (Figure
5) is now recognized to involve multiple signals and distinctly regulated pathways
16

48

. To

fully activate naïve T cells, a second signal which is delivered by positive co-stimulatory
molecules that are present on antigen presenting cells (APCs) is required. These APC’s
also express negative co-stimulatory molecules that are capable of inhibiting T cell
activation. Now it is clear that integration of these positive and negative co-stimulatory
signals by T cells will finally determine the fate and function of the T cell response. The
best-studied co-stimulatory interactions are those of CD80 and/or CD86 molecules on
antigen presenting cells (APCs) with CD28 or CTLA-4 on the T-cell surface 49 and CD40
engagement of its transiently expressed ligand CD154 on the T-cell surface. A positive
stimulus to T-cell activation results from each of these co-stimulatory interactions, with
the exception of CTLA-4 ligation by CD80 or CD86, which results in a negative signal.
Other positive co-stimulatory molecules are ICOS, CD134, CD30, 4-IBB, CD27 and
CD70 which deliver positive co-stimulation under certain circumstances

50

. The negative

co-stimulatory molecules delivering negative co-stimulation signal are Programmed
death 1 (PD-1), and CTLA4

50

. Mice that are genetically deficient for PD-1 develop

lymphoproliferative and autoimmune diseases, demonstrating a role in lymphocyte
deactivation and tolerance 51-52 .

PD-1 (CD279) is an inhibitory receptor expressed on activated T, B, and myeloid
cells 53 . PD-1 is a member of the immunoglobulin (Ig) superfamily, shares a 23% identity
with CTLA-4 and has two ligands with distinct expression patterns: PD-1 Ligand 1 (PDL1; B7-H1) and PD-L2 (B7-DC). PD-L1 is expressed on resting T cells, B cells, DCs,
and macrophages and is further up-regulated upon activation

54, 55

. PD-L1 has a tissue

distribution profile distinct from that of the other B7 family members. PD-L1 has been

17

detected in lymphoid as well as in nonlymphoid organs

56-57

, including vascular

endothelial cells and pancreatic islet cells. In contrast, PD-L2 is inducibly expressed only
on DCs and macrophages

57

. In-vitro studies have shown that engagement of PD1 by its

ligands inhibits proliferation and cytokine production by antigen-specific CD4+ and
CD8+ T cells

58

.

In-vivo studies have shown that PD-L1 expressed on cardiac

endothelial cells plays an important role in downregulating a cytotoxic T-cell–mediated
form of transient myocarditis 59 .

Figure 5. Schematic representation of Co-stimulatory molecules in T cell activation.
Activation of T cell requires two signals, first engagement of T cell receptor with MHC
peptide complex and ligation of co-stimulatory molecules on T cells with their respective
ligands on antigen presenting cells. T cells receiving both signal 1 and positive costimulation will proliferate and will produce cytokine. However, co-stimulatory
molecules such as CTLA4 and PD1, can lead to negative T cell signaling resulting in
reduced cell proliferation and cytokine production (Gao, et al 2003).
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1.4.2

Role of PD-1 and its ligand PD-L1 in transplantation:

PD-1-PD-L1 interactions control engraftment of solid organ and graft versus host
disease at several levels

60

. PD-1 and PD- L1 both are significantly upregulated on

alloreactive T cells in transplant recipients

61-62

. Sandner et al showed that the

administration of blocking anti-PD-L1 monoclonal antibody resulted in enhancement of
alloantigen-driven T cell expansion in- vivo and promoted Th1 differentiation and
accelerated graft rejection

61

. In a model of MHC class II- mismatched (bm12- into-B6

and B6- into-bm12 models) cardiac allografts it was shown that blocking PD-L1
expression caused accelerated rejection. This study also indicated that PD-L1 plays an
important role in regulating CD4+ T-cell mediated alloimmune responses against cardiac
allografts. In this allograft model, PD-L2 does not play an important role in regulating
alloimmune response

63

. In contrast, administration of a PD-L1-Ig fusion protein that

triggers PD-1 negative signaling prevents allograft rejection and facilitates tolerance
induction when combined with anti-CD154 antibody or suboptimal doses of rapamycin
50

. These studies demonstrate the negative regulatory function of the PD-1 pathway in

organ transplantation. Noritaka et al showed that blockade of the PD-1/ PD-L1 pathway
upregulated IFN gamma and TNF alpha and enhanced the proliferation of smooth muscle
cells (SMCs) and CAV

64

. In some transplantation tolerance studies it has been shown

that PD- L1 expression by the endothelium is required to achieve cardiac allograft
tolerance in a fully allogeneic mismatched model 65 . Many other studies demonstrated the
important role of PD-L1 for induction and maintenance of peripheral transplantation
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tolerance through its ability to alter the balance between pathogenic and regulatory T
cells 66 .

1.4.3 Cytokine and che mokine expression in cardiac allograft rejection.

Chemokines are a large family of low-molecular-weight (8- to 11-kDa) cytokines
that mediate cellular trafficking

67

. They are expressed by endothelial cells, lymphocytes

and smooth muscle cells that attract and in turn activate a variety of inflammatory and
non- inflammatory cells and thus mediate directional migration of immune cells to sites of
inflammation and injury 68 . The chemokine superfamily is divided into 4 subfamilies C,
CC, CXC, and CX3C based on the presence of a conserved cysteine residue at the amino
terminus. The C subfamily consists of XCL1 and XCL2, which attract lymphocytes. CC
chemokines predominantly recruit mononuclear cells

67

. The CXC chemokines are

further distnguished by the presence or absence of the sequence glutamic acid- leucine–
arginine (ELR) near the amino terminal. ELR+CXC chemokines are neutrophil
chemoattractants with angiogenic properties. ELR-CXC chemokines are chemoattractants
of lymphocytes with angiostatic properties

69

. The fourth subclass of chemokines is

CX3C subfamily; CX3CL1 is the only known member of this subfamily 67 .

The Chemokine actions are mediated by binding to 7-transmembrane spanning G
protein– coupled receptors (GPCR)

70

. These are heterotrimeric G proteins. The

chemokine receptors undergo internalization and phosphorylation following ligand
binding. Chemokines can also bind to glycosaminoglycan (GAG) on the cell-surface or
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within the extracellular matrix. Although this binding does not generate cell signals, it
maintains stable concentration gradients from the site of chemokine production

71

. In

addition to their trafficking properties, chemokines have also been shown to have several
extrachemotactic properties, such as cellular activation and differentiation.

1.4.4

Role of chemokines in acute and chronic cardiac allograft re jection.

Multiple clinical studies have shown that donor endothelial cells, T cells, B cells
and macrophages can all interact with each other and secrete different sets of chemokines
69

. Chemokines contribute to the onset of acute rejection. After transplantation the levels

of chemokines such as CCL2 (MCP-1), CCL5 (RANTES), CXCL9 (MIG), CXCL10 (IP10), CCL3 (MIP-1alpha) and CCL4 (MIP-1beta) increases in cardiac allograft (Figure 6).
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Figure 6. This plot depicts the expression of chemokines at various stages in immune
responses to allografts. The early stages are dominated by neutrophils and monocytes,
followed by NK cells, T lymphocytes, and macrophages, and eventually by smooth
muscle–like cells and a number of chemokines are expressed such as MIG/CXCL9,
CCL5 to form GAD lesion in later stage of transplant rejection (Shimizu et al 2003).

It has been shown that CCL3, CCL4, and CCL5/RANTES stimulate T-cell
differentiation into Th-1 subtype. This effect is mediated both directly and indirectly via
interleukin (IL)-12. In contrast, CCL2/MCP-1 polarizes T- lymphocyte differentiation to
Th-2 subtype by suppressing IL-12 expression and stimulating IL-4 expression

70

. In

addition, CCL2 also appears to have a direct effect on T- lymphocyte differentiation
toward Th-2 subtype. Among CXCR3-binding chemokines, CXCL10/IP-10 has been
shown to enhance generation of tumor-specific T cells and protective immunity in an IL12 gene therapy model. CXCL10/IP-10 has also been shown to be important in
22

generation of T- lymphocyte effector

function.

Another study examined

the

extrachemotactic properties of CXCL9/MIG 70 . CXCL9/MIG was shown to stimulate Tlymphocyte proliferation and increase the number of interferon gamma (IFNg) producing
T cells both in-vivo and in-vitro. These stimulatory effects are independent of IL-2, but
are controlled by IFNg, and are found to occur in major histocompatibility complex
(MHC) class I and II and totally mismatched cardiac transplants. These studies show the
extrachemotactic properties of some chemokines that is similar to the role of several
classic cytokines. In transplants these chemokine regulate the recruitment of
monocyte/macrophages, activated T cells, NK cells and eosinophil and thus contribute to
the onset of acute rejection

72-73

source of this chemokine

74

. The infiltrating macrophages have been identified as a

. It is known that chemokines MCP-1/CCL2, and

RANTES/CCL5 are the dominant mediators in recruiting monocytes to the rejecting
organ

75

. Studies have demonstrated that blocking of either MCP-1 or RANTES

substantially reduces intragraft macrophage and T cell accumulation and attenuates
allograft rejection

76-77

. Chemokines also play an important role in cardiac allograft

vasculopathy. Chemokines can directly contribute to vascular remodeling and
angiogenesis. The chemokines can contribute to both recruitment and expansion of
intimal cells in arterial lesions

68

. In endomyocardial biopsies increased expression of

MIG/CXCL9 has been associated with acute rejection 78 .

1.4.5

Role of IL1R1 and IL1R2 and their association with cardiac allograft
re jection:
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The IL-1 family is comprised of 11 members. These members include IL1alpha,
IL1beta, IL1 receptor antagonist, IL-18, IL-33 and IL1F5- IL1F-10. IL-1 functions as a
growth factor for fibroblasts, keratinocytes, lymphocytes, and SMCs and enhances
activation of B and T cells, many of the cell types implicated in inflammation

79

.

Moreover, IL-1 is an activator of endothelial cell gene expression and is known to
modulate the presence of cell adhesion molecules such as E-selectin on the endothelial
surface. These IL1 family members signal through a group of closely related receptors.
The receptors contain extracellular immunoglobulin domains and a Toll/ IL1 receptor
(TIR) domain in the cytoplasmic portion 80 . IL-1 affects target cells through two distinct
types of transmembrane receptors that have a nearly identical extracellular domain 81 . It is
known that Interleukin-1 (IL-1) alpha and beta are major proinflammatory cytokines that
function in immunomodulatory and inflammatory processes, which occur mainly via
interactions with the IL-1 type I receptor (IL-1RI)

81

. IL-1R1 has a 213-amino acid

cytoplasmic domain that is important for signal transduction. IL-1R1 is found mainly on
T cells, fibroblasts, keratinocytes, and hepatocytes

82

. The IL-1/IL-1RI interaction has

important effect on cardiovascular events, such as atherosclerosis, myocardial infarction,
vascular wall remodeling, and the response to vascular injury

83-85

. However, IL-1

activity is tightly regulated by IL-1 receptor type II (IL1R2). IL-1R2 is a non-signaling
decoy receptor that negatively regulates the activity of IL-1, a pro- inflammatory cytokine
86

. IL-1R2 has a shorter cytoplasmic domain and does not transduce the signal. IL-1R2 is

found predominantly on B cells, macrophages, and neutrophils 82 . In the transplant setting
it is known that proinflammatory cytokines mediate ischemia-reperfusion injury and
stimulate immune responses that leads to acute graft rejection. Upregulation of
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interleukin-1 (IL-1) occurs very early after graft reperfusion 87 as has been demonstrated
in human heart transplants

88

. It has been demonstrated in a rat model that soluble IL-1

type-2 receptor gene transfer lessens cardiac allograft rejection 82 .
In the Cardiac Allograft Rejection Gene Expression Observational (CARGO) study 11
genes were validated on RNA extracted from peripheral blood mononuclear cells. This
gene expression profiling was correlated with findings in endomyocardial biopsies that
had moderate to severe cardiac allograft rejection. In this study, IL-1R2 was found to
correlate most strongly with resolution of acute rejection and stable graft function 89-90 .

1.4.6

Patte rn recognition molecules and their endogenous ligands (Toll like
receptor, Hyaluronan).

Toll like receptors (TLRs) are a family of pattern recognition proteins that detect
both microbes and host derived molecular patterns. These pattern recognition proteins are
expressed on macrophages, dendritic cells and epithelial cells. When ligands bind to
TLRs, they activate transcription factors that lead to production of inflammatory
mediators. These TLRs play an important role in the innate immune response and
subsequently lead to induction of adaptive immune response against pathogens

91

. There

are at least 11 mammalian TLRs that have been identified. Each TLR recognizes distinct
pathogen associated molecular patterns (PAMPs). Some of the examples of exogenous
ligands for TLRs are Triacyl lipopeptides, peptidoglycans, dsRNA, LPS, Flagellin and
unmethylated CpG DNA. In addition to the exogenous ligands, it is known that TLRs are
receptors for endogenous stimulators that are released from damaged tissues and thus
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lead to noninfectious inflammatory response

92-93

. The endogenous TLR ligands do not

interact with corresponding receptors in quiescent conditions because of their different
cellular compartmentalization. But in certain pathological conditions, these endogenous
molecules are released from injured or necrotic tissues and cells through nonconventional lysosomal route

94-95

. These endogenous molecules activate TLRs and

initiate a protective inflammatory response and the repair of damaged tissues. For this
reason endogenous ligands for TLRs are called alarmins and serve as early warning
signals. As alarmins are released after tissue injury and cell death, they have similar
response as PAMPs and thus are collectively called as damage associated molecular
patterns (DAMPs)

96

. Some of the examples of endogenous ligands for TLRs are

hyaluronan 97 . HMGB1, CD138, HSP60 and HSP70 98-99 .
.

1.4.7

Hyaluronan

Hyaluronan (HA) is an important structural component of the extra cellular matrix
(ECM). HA is a glycosaminoglycan polymer composed of repeating disaccharides of beta
glucuronic acid and N-acetyleglucosamine covalently bound end to end into a simple
linear glycosaminoglycan 100 . HA is synthesized locally in the tissue by various isoforms
of hyaluronic acid synthase that is present in the plasma membrane of mesenchymal cells
as high molecular weight polymer, its molecular weight is up to 107 Da 101-102 . A local
degradation of HA occurs in the tissue and it is also cleared through the lymphatics. The
HA clearance from the blood is extremely rapid and occurs within minutes
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101

. Even

though reticuloendothelial cells in the lymph nodes catabolize a large proportion of
hyaluroran, some reaches the general circulation. Most of the circulating hyaluronan is
taken up via receptor mediated endocytosis and degraded by liver sinusoidal endothelial
cells 103-104 . The damage to the sinusoidal endothelial cells, such as from ischemia or drug
toxicity, is, therefore reflected by an increased serum content of hyaluronan 105 .

HA can be broken down into fragments by a number of enzymatic and nonenzymatic processes

99

. Small molecular weight HA has been implicated in several

biological processes including angiogenesis, cell proliferation, maturation, migration,
activation of protein tyrosine kinase cascades, and inflammatory gene expression

106

.

These small or low molecular weight HA fragments are increasingly being characterized
as an endogenous danger signal that promotes the expression of immune mediators.
Small HA fragments may therefore activate repair processes and signal the immune
recognition system that injury has occurred 107 . Tesara et al showed in murine models that
these fragments of HA induce DCs to upregulate co-stimulatory molecules CD40 and
CD86 and produce the proinflammatory cytokine TNF-alpha 108 .

It has been established that the cell surface adhesion molecule CD44 is the
principal receptor for hyaluronic acid in mouse and human. CD44 has been implicated in
lymphocyte homing, embryonic development, T cell activation. CD44 is also expressed
on monocyte/macrophages 109 .
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1.4.8

Hyaluronan Role in transplantation:

Some studies involving solid organ transplants have found an association between
TLR4 and allograft rejection. One study linked expression of TLR4 activation on the
cardiac allograft to the development of CAV. In a number of human heart transplant
recipients, expression of TLR4 and resultant IL-12 and TNF-α production was
significantly elevated in patients with allograft endothelial dysfunction, which is a
predictor of subsequent development of CAV

110

. McDaniel et al demonstrated that

increased expression of TLR2 and TLR4 correlated with cardiac allograft rejection

111

.

Johnsson et al showed that during allograft rejection there is local accumulation of
hyaluronan within the transplanted organ. Accumulation of HA has been seen in cases of
cardiac, renal and intestinal transplants. The increased tissue content of hyaluronan can
most probably be attributed to an increased synthesis that is stimulated by cytokine
released by graft infiltrating immunocompetent cells

112

. In murine orthotopic lung

transplant model it has been demonstrated that accumulation of HA could contribute to
Bronchiolitis Obliterans Syndrome by directly activating innate immune signaling
pathways that promote allograft rejection and neutrophilia

113

. In one of the study it was

suggested that fragments of hyaluronan can act as innate immune agonists that activate
alloimmunity. Using a murine invitro culture it was shown that 135KDa fragment of HA
induces DC maturation and initiate alloimmunity and this priming of alloimmunity by
HA activated DCs was dependent on signaling via TIR associated protein and TLR2 and
TLR4. Moreover in a murine skin graft model, the same group demonstrated that HA is
accumulated during skin transplant rejection 108 .
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It has been proposed in the setting of transplantation that both antigen
independent and dependent mechanisms initiate graft injury leading to production of HA
fragments (Figure 7)

108

. After transplantation the allograft undergoes ischemia

reperfusion injury allowing the release of fragments of hyaluronan. The hyaluronan
fragments are recognized by DCs (of either donor or recipient origin) mostly via TLR4
but with some minor participation of TLR 2.

The TLR signal adaptor TIRAP, which is downstream of TLRs 2 and 4 is
important for the upregulation of co-stimulatory molecules and the production of
inflammatory cytokines by fragmented hyaluronan activated DCs. It has been shown that
TIRAP signaling is important for fHA-activated DCs to prime allogeneic T cells. Primed
allogeneic T cells then contribute to alloantigen-dependent graft injury. MyD88 is also
critical for the inflammatory response and Trif participates in this response 108 .
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Figure 7. Schematic representation of TLRs and hyaluronan fragments in allograft
rejection (Tesar et al 2006).

1.5 Compartme ntalization of Acute and Chronic Rejection.

Although we know that immune responses to cardiac allografts can result in acute and
chronic rejection, it is unclear what directs the immune response to localize to different
compartments of the heart. Acute rejection is characterized by interstitial infiltrates T
cells and macrophages. However, chronic rejection is characterized by narrowing of the
coronary arteries. Acute and chronic rejection attack two different compartments of heart.
The mechanisms underlying this compartmentalization of acute and chronic rejection are
not known. In this dissertation we will examine the role of different biological molecules
that are involved in the cardiac allograft rejection.
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CHAPTER II

ACUTE AND CHRONIC REJECTION: COMPARTMENTALIZATION AND
KINETICS OF COUNTERBALANCING SIGNALS IN CARDIAC
TRANSPLANTS

2.1 Abstract

Acute and chronic rejection impact distinct compartments of cardiac allografts.
Intramyocardial mononuclear cell infiltrates define acute rejection, whereas chronic
rejection affects large arteries. Hearts transplanted from male to female C57BL/6 mice
undergo acute rejection with interstitial infiltrates at 2 weeks that resolve by 6 weeks
when large arteries develop arteriopathy. These processes are dependent on T cells
because no infiltrates developed in T cell deficient mice and transfer of CD4 T cells
restored T cell as well as macrophage infiltrates and ultimately neointima formation.
Markers of inflammatory macrophages were upregulated in the interstitium acutely and
decreased as markers of wound healing macrophages increased chronically. Programmed
cell death protein, a negative co-stimulator, and its ligand PDL1 were upregulated in the
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interstitium during resolution of acute rejection. Blocking PDL1:PD1 interactions in the
acute phase increased interstitial T cell infiltrates. Toll Like Receptor 4 and its
endogenous ligand hyaluronan were increased in arteries with neointimal expansion.
Injection of hyaluronan fragments increased intragraft production of chemokines. Our
data indicate that negative co-stimulatory pathways are critical for the resolution of acute
interstitial infiltrates. In the arterial compartment recognition of endogenous ligands
including hyaluronan by the innate toll like receptors may support the progression of
arteriopathy.

2.2 Introduction

Immune responses to cardiac allografts can result in acute and chronic rejection. In
addition to differences in kinetics, acute and chronic rejection attack two different
compartments of the heart. Acute rejection is defined by interstitial mononuclear cell
infiltrates with associated myocyte damage as seen in endomyocardial biopsies 1 . In
contrast, chronic rejection primarily involves large coronary arteries. Chronic rejection is
characterized by diffuse intimal hyperplasia containing mononuclear leukocyte infiltrates.
Additional mononuclear leukocyte infiltrates are frequently present in the media and
adventitia

2-4

. This pathological process is diagnosed by angiography or intravascular

ultrasound and is labeled cardiac allograft vasculopathy (CAV). The incidence of
interstitial pathology decreases with time after transplantation in most patients, and one
multicenter study concluded that routine endomyocardial biopsies were not of diagnostic
value after 5 years except in patients with high risk for acute rejection 5 . In contrast, the
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incidence of CAV increases progressively after transplantation. As a result, advanced
CAV is often reported with little or no infiltrates in endomyocardial biopsies 2 .

Mechanisms underlying compartmentalization of acute and chronic rejection are not
known. However, the infiltrates in acute and chronic rejection are predominantly
comprised of T cells and macrophages, which are regulated by many positive and
negative co-stimulatory signals. The most extensively studied co-stimulatory receptors on
T cells belong to the CD28 family and include the activating receptor CD28 and
inhibitory receptor CTLA-4, both of which bind B7-1/CD80 and B7-2/CD86 ligands.
Another member of the CD28 family is PD1 (CD279), an inhibitory receptor that binds to
PDL1 and PDL2 (CD274 and CD273) that are expressed on antigen presenting cells

6-8

.

In addition, PDL1 is constitutively expressed by various parenchymal cells including
cardiomyocytes

and

can be

induced

on endothelial cells

6,

9

.

Therefore,

compartmentalized pathology could result from differentially expressed ligands for
positive and negative co-stimulatory receptors on T cells during the process of rejection.
T cells in turn produce cytokines that direct macrophages to differentiate into performing
acute inflammatory functions or chronic wound healing functions

10

. Clinically,

macrophages are routinely identified in biopsies by a universal macrophage marker, such
as CD68

1, 11, 12

. Inflammatory macrophages (M1 macrophages) release cytokines

including IL-1beta and TNFalpha, chemokines such as MIG/CXCL9 and MCP-1/CCL2,
as well as reactive oxygen species that promote acute interstitial infiltrates

10

. Increased

expression of MIG/CXCL9 in endomyocardial biopsies has been associated with acute
rejection in clinical studies

13

, and infiltrating macrophages have been identified as a
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source of this chemokine

12

. In contrast, wound healing macrophages (M2 macrophages)

produce growth factors such as TGF beta and VEGF that are elevated in fibrotic
processes. The balance between inflammatory and wound healing macrophages has not
been investigated in either acute or chronic rejection of cardiac transplants.

Another set of genes associated with acute rejection was identified in the
multicentered Cardiac Allograft Rejection Gene Expression Observational (CARGO)
study. This study was designed to establish gene profiles in peripheral blood
mononuclear cells that distinguish patients with stable transplants from patients who
developed acute rejection 14 . In the CARGO study, the gene encoding the decoy receptor
for IL-1 (IL-1R2) correlated most strongly with resolution of acute rejection and stable
graft function 15, 16 . Although IL-1R2 is the predominant receptor for IL-1 on monocytes
17

, the expression of this decoy receptor has not been examined on macrophages in the

interstitial or arterial compartments of cardiac transplants.

Based on these clinical observations, we hypothesized that differential expression
of critical molecules in the interstitial and arterial compartments accounts for the distinct
localization of acute and chronic rejection in cardiac transplants. To test this hypothesis,
we examined cardiac allografts that were transplanted from male to female C57BL/6 (B6)
mice. These allografts elicit an

acute rejection that spontaneously resolves and

progresses to CAV. This enabled us to analyze the pathological process in the interstitial
and arterial compartments at different stages. Using immunohistology and cell transfers,
we demonstrated that CD4 T cells are required to orchestrate acute and chronic infiltrates
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of inflammatory macrophages. An extensive PCR screen of microdissected tissue
samples revealed sets of genes that were differentially expressed in the interstitial and
arterial compartments. During acute rejection B7-1/CD80 and B7-2/CD86, which are
ligands for both positive and negative co-stimulatory receptors on T cells, were more
highly upregulated in the interstitial than arterial compartment. In addition PDL1/CD274
was upregulated in the intersititium. The functional relevance of negative co-stimulation
to the resolution of the acute interstitial infiltrate was tested by treatment with a blocking
antibody to PDL1. This increased interstitial but not arterial infiltrates of PD1 expressing
T cells and resulted in acute rejection of cardiac allografts. Acute rejection was
accompanied by a significant increase in chemokines in the interstitial compartment,
particularly MIG/CXCL9 that has been found in endomyocardial biopsies from patients
with findings of acute cellular rejection12,

13

. Finally, IL-1R2 was upregulated during

acute rejection in both the interstitial and arterial compartments and then subsided in
chronic rejection. These data localize clinically relevant markers in the context of
pathological findings.

2.3 Materials and Methods

2.3.1 Mice

Male B6 (H2b), Female B6 and Female B6.129S7-Rag1tm1Mom/J (SCID) mice
were purchased from Jackson Laboratories (Bar Harbor, ME) for use at 8-12 weeks of
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age. The B6.129S7-Rag1tm1Mom/J (SCID) are homozygous for the Rag1tm1Mom mutation
and produce no mature T cells or B cells. These mice have a non-leaky severe combined
immunodeficiency phenotype. The female C57BL/10NA;-(Tg)TCR Marilyn- (KO) Rag2
N11, N2 mice (H-2b, Marilyn), age 6 to 8 weeks, were obtained as a generous gift from
Polly Matzinger (National Institutes of Health, Bethesda, MD) and Olivier Lantz
(INSERM, Paris, France). All animal studies were approved by the institutional animal
care and use committee at the Cleveland Clinic Foundation.

2.3.2

Heterotopic heart transplantation

Male C57BL/6 hearts were transplanted into female C57BL/6 or SCID.
Heterotopic heart transplantation was performed under pentobarbital anesthesia. The
donor aorta and pulmonary artery were anastamosed to the recipient’s abdominal aorta
and inferior vena cava respectively. Oral Tylenol was used at a dose of 3mg/ml of
drinking water as an analgesic three days following surgery.

Graft function was

monitored every week till the end of the experiment. These animals were sacrificed
either at 2, 6, 8 or 10 weeks after transplantation.

2.3.3

CD4 T cell isolation, sorting and transfer

CD4 T-cells were isolated from female Marilyn CD4 T-cell receptor transgenic
mice, in which all T cells are specific for the male minor transplantation antigen
presented by H-2I-Ab MHC. Spleens from these transgenic mice were teased into single
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cell suspensions in PBS + 2% fetal bovine serum. The red blood cells were lysed using
ACK lysis buffer (Gibco, Life Tecnologies, Grand Island, NY). Cells were washed and
incubated with the following mixture of FITC- labeled antibodies from BD Pharmingen
(San Jose, CA) for negative selection: CD8a, CD19, CD11c, CD11b, CD117, NK1.1 at
1:500 dilution. Labeled cells were removed by flow sorting and the unlabeled CD4 cells
were transferred to SCID mice 7 days following cardiac transplantation. These cells were
>95% CD4+ by flow cytometry. The time of transfer was designed to avoid the effects
of nonspecific inflammation from the surgical procedures.

2.3.4

Treatment with blocking antibody or hyaluronan fragments

Recipients were injected intraperitoneally with 3 doses of 200ug of purified
IgG2a rat monoclonal antibody to PDL1 (clone 10F.9G2) or 200ug of isotype control
(clone LTF-2) antibody (BioXCell, West Lebanon, NH) on alternate days in the second
week or sixth week after transplantation.
Highly purified fragment preparations of hyaluronan (Lifecore Biomedical, LLC) were
electrophoretically separated as previously described19 . A 100ug dose of low molecular
weight (4.7 or 35kD) hyaluronan was administered intraperitoneally daily from the day of
transplantation for 2 weeks. Controls were administered equal volumes of the PBS
diluent.
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2.3.5

Histology and immunohistochemistry

Full cross-sections through the cardiac grafts were obtained at the time of
sacrifice and fixed in methanol acetic acid (60% methanol; 10% anhydrous acetic acid;
30% water). Deparaffinization and antigen retrieval were achieved with 2 incubations in
Trilogy (Cell Marque, Rocklin, CA) for 30 minutes in a pressure cooker (125C). The
deparaffinized slides were cooled, rinsed with water and incubated 20 minutes in 0.3%
hydrogen peroxide in 80% methanol followed by 10 minutes in Protein Block (Dako,
Carpinteria, CA). Sections were incubated with primary antibodies diluted with AB
Diluent (Dako Carpinteria, CA) for 1-2 hours at room temperature. For rabbit primary
antibodies Super picture polymer detection kit (Invitrogen, Carlsbad, CA) was used, and
for rat and goat primary antibodies Rat and Goat HRPPolymer (Biocare medical,
Concord, CA) were used. Staining was visualized with DAB substrate kit for peroxidase
(Vector Laboratories Inc, Burlingame, CA) before counterstaining with hematoxylin. The
following primary reagents were used: polyclonal rabbit antibody to CD3 (Abcam,
Cambridge, MA), rat monoclonal antibody to mouse Galectin-3 (Mac-2; Cedarlane,
Burlington, 8 NC), rabbit polyclonal antibody to Chitinase 3- like 3 (Ym-1; Stem Cell
Technologies, Vancouver, Canada), polyclonal goat antibody to PD-1 (R&D systems Inc,
Minneapolis, MN), rat monoclonal antibody to mouse Foxp3 (eBiosciences, San Diego,
CA), rabbit polyclonal antibody to Ki67 (Novacastra, Buffalo Grove, IL), rat monoclonal
antibody to mouse CD44 (Abcam, Cambridge, MA), and biotinylated hyaluronic acid
binding protein (Millipore, Billerica, MA).
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2.3.6

Laser capture microdissection and real time RT PCR

Frozen sections on PET-Membrane slides (Leica, Buffalo Grove, IL) stained with
Arcturus Histogen solution (Life Technologies, Grand Island, NY) were microdissected
on a Leica AS-LMD microscope. Samples were collected in RNAlater. Total RNA was
isolated using the RNeasy micro kit and reverse transcribed with the RT2 PreAMP cDNA
synthesis kit (QIAGEN, Gaithersburg, MD). Expressions of 86 genes (Table 1) was
screened with a customized PCR array kit (QIAGEN). Eighteen genes were analysed in
additional samples by qPCR using the ddCT method 21 , calibrated to (control sample) and
normalized to B-actin. TaqMan assay numbers for all genes measeured are listed in
(Table 2).

39

Table 1. Complete list of genes on microarray.
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Table 2. PCR primer sequences.
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2.3.7

Isolation of graft infiltrating cells for flow cytometry

Cells infiltrating the graft were isolated as previously described 18 . Briefly, grafts
were removed after perfusing the recipient with RPMI media to flush cells from the
circulation. The apical half of the graft was weighed and incubated 1 h at 37C in RPMI
with Type II collagenase (Sigma- Aldrich) before pressing through a 40 μm filter. The
collected cells were washed twice in RPMI, counted and stained for phenotypic surface
markers (CD45, CD4, CD11b, F4/80, PDL1, PD1 and IL1-R2 from BD Bioscience, San
Jose, CA; eBioscience, San Diego, CA, USA). Flow cytometry was performed using a
FACSCalibur (BD Biosciences) cytometer and FlowJo analysis software (Tree Star Inc.,
Ashland, OR, USA). The forward scatter and FL1 (CD45+) channels were used to gate
on leukocytes followed by analysis of the specific leukocyte populations. For each
sample, 2x105 events were accumulated.

2.3.8

Quantitation of che mokines, hyaluronan and IL-1 receptors in allografts

Grafts were removed and homogenized in 500ul of proteinase inhibitor. Then 1
ml of 1.5% Triton X-100 in PBS was added before shaking 30 minutes at 4C. After
pelleting cell debris, the supernatants were collected and total protein concentration
quantified by Coomassie Plus Protein Assay Reagent kit (Pierce, Thermo Fisher
Scientific, Rockford, IL). Protein concentrations were determined using ELISA kits for
CXCL9, CCL5, CCL2 and hyaluronan from R&D Systems (Minneapolis MN), and IL1R1 and IL-1R2 from US Biological (Marblehead MA).
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2.3.9

Analysis of gene expression by quantitative RT-PCR

Total RNA was isolated from interstitium and arterial compartment using RNeasy
micro kit (Qiagen, Gaithersburg, MD) followed by cDNA preparation using RT2
PreAMP cDNA synthesis kit (QIAGEN, Gaithersburg, MD). PCR was performed with
FAM dyelabeled probes (Applied Biosystems, Grand Island, NY) for mouse cd274
(PDL1), TLR2, TLR4, Actb and Mrpl32 (gene assay ID nos. Mm00452054_m1,
Mm00442346_ml,

Mm00445273_ml,

Mm00607939_Sh

and

Mm00777741sH,

respectively). The expression level of the housekeeping gene is subtracted from the
expression level for each test gene. These gene expression levels were compared to the
isograft controls.

2.3.10

Statistical Analysis

Statistical analyses were performed using GraphPad Prism 5.0 software
(GraphPad Software Inc. San Diego, CA). Differences between groups for cell numbers
and chemokine content were evaluated using an unpaired Student’s t-test.
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2.4.

Results:

2.4.1

Hearts transplanted from male to female B6 undergo acute re jection that

transitions into chronic re jection.

Female recipients of male B6 hearts were sacrificed 2 or 6 weeks after
transplantation to assess acute and chronic manifestations of rejection. At 2 weeks,
allografts contained diffuse interstitial infiltrates of T cells and macrophages with limited
periadventitial involvement of larger arteries (Figure 8A,B). By 6 weeks interstitial
infiltrates diminished, and about half of the large arteries developed adventitial and
intimal mononuclear infiltrates predominantly composed of macrophages (Figure 8C,D).
Isograft controls did not exhibit pathological changes (Figure 9A- D).

Most macrophages in the acute and chronic lesions were intensely positive for
Galectin-3, a marker of activated macrophages that contribute to cardiovascular disease
22, 23

. These macrophages were elongated with cytoplasmic projections and frequently

formed clusters (Figure 8B inset). Few macrophages in either the acute or chronic
infiltrates were positive for Ym-1, a marker for M2 macrophages

10

. Moreover, these M2

macrophages were scattered as individual large ovoid cells (Figure 10A,B). We also
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found limited numbers of Foxp3 positive regulatory T cells in interstitial and arterial
compartments (Figure 10C,D).

Figure 8. Immunoperoxidase stains of acute and chronic infiltrates in cardiac allografts.
At 2 weeks (top row), allografts contained a diffuse interstitial infiltration of CD3 T cells
(A) and Galectin-3+ macrophages (B) with limited periadventitial involvement of larger
arteries (right side of figures). The macrophages displayed cytoplasmic projections on
high power (inset). At 6 weeks, the interstitial infiltrates diminished, and large arteries
developed adventitial and intimal infiltrates composed of CD3 T cells (C) and larger
numbers of macrophages (D). Original magnifications 200x (inset 600x).
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Figure 9. Immunoperoxidase stains of mononuclear infiltrates in cardiac isograft at 2 and
6 weeks in wild type recipients. At 2 weeks (top row), male cardiac isografts to wild type
male recipients contained few CD3 T cells (A) and Galectin-3 positive macrophages (B)
with no pathology. At 6 weeks (second row), the male cardiac isografts to wild type male
recipients contained few CD3 T cells (C) and Galectin-3 positive macrophages (D) with
no pathology. Original magnifications 200x.
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Figure 10. Only limited numbers of macrophages in either the 2 week (A) or 6 week (B)
infiltrates were positive for Ym-1 (Chitinase 3-like 3) a marker for M2 macrophages.
These M2 macrophages were scattered as individual large ovoid cells (inset). Limited
numbers of Foxp3 positive regulatory T cells were present both in interstitial and arterial
compartments at 2 weeks (C) and 6 weeks (D).

2.4.2

CD4 T-cells orchestrate acute and chronic rejection

Because H-Y peptides are presented in the context of MHC class II molecules, we
tested the requirement for CD4 T cells in generating acute and chronic pathology. Hearts
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were transplanted from wild type male B6 mice into female B6 Rag1 deficient recipients
(B6.RAG-/-), which lack mature T and B cells. One week later we reconstituted the
recipients with 2-3x104 CD4 T cells from transgenic female B6 mice that express T cell
receptors for H-Y peptides in the context of H2-IAb (Marilyn mice). Female B6.RAG-/recipients were sacrificed at 2 and 6 weeks after cell transfer. Two control groups were
used: Isografted hearts from female B6 mice into female B6.RAG-/- recipients, which
were reconstituted with 2x104 CD4 T cells from Marilyn transgenic mice, and allografted
hearts from male B6 mice into female B6.RAG-/- recipients, which were not
reconstituted. In the absence of T cell reconstitution, no infiltrates developed in the male
B6 cardiac allografts to female B6.RAG-/- recipients (Figure 11A, B). Similarly, CD4 T
cells from Marilyn mice did not cause infiltrates in isografts to female B6.RAG-/recipients at either 2 (Figure 11C, D) or 6 (Figure 11E, 4F) weeks. However, CD4 T cells
from Marilyn mice reconstituted acute interstitial infiltrates that progressed to CAV in
male B6 cardiac allografts to female B6.RAG-/- recipients. As in wild type recipients,
both acute and chronic infiltrates were composed of T cells and macrophages, but
activated macrophages predominated (Figure 12A-D). An additional group of mice
sacrificed at 10 weeks had more extensive arterial lesions in their allografts, but the T
cells had diminished (Figure 12E), and macrophages increased (Figure 12F). At this time,
the neointima had progressed to contain alpha-smooth muscle expressing cells (Figure
13).
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Figure 11. Immunoperoxidase stains of mononuclear infiltrates of CD3 (A) and
Macrophages (B) in cardiac allograft at 2 weeks in Rag1-/- recipients with male wild type
heart. Female wild type heart transplanted to female RAG-/- recipients reconstituted with
Marilyn CD4 T cells, contained few CD3 T cells (C) and Galectin-3 positive
macrophages (D) at 2 weeks. At 6 weeks, no arteries developed vaculopathy and only
few CD3 T cells (E) and few Galectin-3 positive macrophages (F). Original
magnifications 200x.
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Figure 12. Male hearts transplanted to female RAG-/- recipients reconstituted with
Marilyn CD4 T cells. At 2 weeks, allografts contained diffuse interstitial infiltrates of
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CD3 T cells (A) and Galectin-3+ macrophages (B) with limited periadventitial
involvement of larger arteries. At 6 weeks, the interstitial infiltrates diminished, and large
arteries developed adventitial and intimal infiltrates of CD3 T cells (C) and large
numbers of macrophages (D). At 10 weeks, the arterial lesions contained decreased
numbers of CD3 T cells (E), and increased macrophages (F). Original magnifications
200x (A-D) and 40x (E, F).

Figure 13. Male hearts transplanted to female RAG-/- recipients reconstituted with
Marilyn CD4 T cells and sacrificed at 10 weeks. Large artery with limited numbers of T
cells (A), large numbers of macrophages in the neointima as well as adventitia (B), and
alpha-smooth muscle expressing cells in the neointima (C). Original magnifications
200x.

2.4.3

Mediators expressed more highly in the interstitial than in the arterial

compartments during acute and chronic rejection

Laser capture microdissection was used to isolate tissue from the interstitial and
arterial compartments of allografts and isografts (Figure 14). Real Time PCR array
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analysis was performed on tissue captured from the two compartments to evaluate the
expression of 86 different genes in a single plate. Table 3 lists the most highly
upregulated genes in the interstitium of allografts compared to isografts at 2 and 6 weeks.
These included the chemokines MIG (CXCL9), RANTES (CCL5) and MCP-1 (CCL2);
the co-stimulatory molecules B7-1/ CD80, B7-2/ CD86, and PDL1 (CD274); IL-1
receptors (IL1R1 and IL1R2); the Toll like Receptors TLR2 and TLR4. The chemokine
genes were more highly upregulated at 2 weeks than at 6 weeks in the interstitium of
allografts compared to isografts. In contrast, TLR2 and 4 increased with time after
transplantation.

Because MIG and MCP-1 are produced by M1 inflammatory macrophages,
additional microdissections were performed and the captured tissues were probed for 6
markers for M1 macrophages (IL-1beta, IL-6, IL-15, IL-18, TNFalpha and Nos2), all of
which were increased more in the interstitium than in the arterial compartment at 2 weeks
(Figure 15B). By 6 weeks, all of the M1 markers had decreased in the interstitium and
increased in the arterial compartment. Changes in MIG and MCP-1 were congruent with
the M1 markers in these samples (Figure 15A). The converse was found for five markers
for M2 macrophages (Ym1, Fizz1, VEGF, TGFbeta, and CD206), which were more
elevated in the arterial compartment than in the interstitum at 2 weeks (Figure 15C). By
6 weeks, these M2 markers had decreased in the arterial compartment and increased in
the interstitium. The exception to this pattern was IL-10, which was most elevated
acutely in the interstitium, but was elevated in at 2 and 6 weeks in both compartments
(Figure 15C).
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Chemokine expression was confirmed on the protein level by ELISA on tissue
homogenates of allografts. These homogenates were prepared from the apex of the heart
that contains myocardium but no large arteries, and therefore, sampled the interstitial
compartment. MIG, RANTES and MCP-1 were all elevated at 2 weeks and diminished
by 6 weeks in parallel with interstitial infiltrates (Figure 16A).

Figure 14.
Procurement of individual vascular
compartments laser capture
microdissection method allowed for the separate dissection of the mouse interstitium and
coronary arteries.
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Table 3. Genes upregulated in microdissected allografts expressed as fold change
compared to isograft.
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Figure 15. Quatitative PCR on 3 microdissected allografts at 2 and 6 weeks expressed as
fold change relative to isografts from the same time points. Confirmation of key
cytokines, receptors and ligands from the initial PCR array (A). Markers for M1
inflammatory macrophages are consistently higher in the interstium (left panel) at 2
weeks (filled bars) than at 6 weeks (open bars), whereas in the arterial compartment
(right panel) these markers are low at 2 weeks and increase by 6 weeks (B). In contrast,
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the converse occurs for markers of M2 wound healing macrophages with the exception of
IL-10 (C). Error bars represent standard errors of the mean of 3 allografts. Differences
between 2 and 6 week values were significant at the P<0.05*; <0.01**; or <0.001***
level as indicated.

Figure 16A. Confirmation of expression of chemokines by ELISA. MIG, RANTES and
MCP-1 were elevated at 2 weeks and then diminished by 6 weeks in the homogenates of
myocardium from cardiac allografts (A).

2.4.4

Expression of IL-1R2 and PDL1 by cells in the circulation and infiltrating

grafts

Because of the potential importance of the decoy receptor for IL-1 and negative
co-stimulatory signals for T cells in resolving the acute interstitial infiltrates, we
investigated the expression of IL-1R2 and PDL1 in more detail. IL-1R2 protein was
elevated in the graft homogenates at 2 weeks by ELISA (Figure 16B).
The increase in PDL1 in interstitial compared to arterial tissue at 2 weeks and 6
weeks was confirmed by qPCR analysis (Figure 16G). Flow cytometry on cells isolated
from the allografts at 2 weeks demonstrated that about 25-30% of CD45 labeled cells
were F4/80+ macrophages, and PDL1 was expressed by almost 80% of these
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macrophages (Figure 16C). This represented a major enrichment compared to the low
percentage of circulating monocytes that expressed PDL1 (16±0.6%; Figure 16D). Local
expansion may contribute to the enrichment of PDL1 expressing macrophages in the graft
because many of the macrophages labeled with the proliferation marker Ki67 in the
interstitial and arterial compartments (Fig 16E, 16F).
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Figure 16 (B-G). Confirmation of expression of the decoy receptor for IL-1 and negative
co-stimulatory ligand PDL1 by ELISA and flow cytometry. IL-1R2 was also elevated in
the allograft compared to isograft homogenates at 2 weeks and to a lesser degree at 6
weeks by ELISA (B). Flow cytometry demonstrated that PDL1 was expressed by
majority the F4/80+ macrophages that were infiltrating the allografts at 2 weeks (C). This
represented a major enrichment compared to the limited percentage of circulating
monocytes that expressed PDL1 (D). Local expansion may contribute to the enrichment
of PDL1 expressing macrophages in the graft because many of the macrophages labeled
with the proliferation marker Ki67 at 2 weeks (E) and 6 weeks (F). Each symbol in the
scattergams represents data from an individual animal. Levels of CD274 (PDL1) mRNA
in interstitial compared to arterial tissue in allografts at 2 weeks and 6 weeks as measured
by qPCR (G).

2.4.5

Blocking PDL1 early prevents resolution of acute interstitial infiltrates

The effects of blocking the negative signals delivered by PDL1 on acute
interstitial infiltrates was tested by treating female B6 recipients of male cardiac
allografts with monoclonal antibody to PDL1 or isotype control antibody on days 8, 10
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and 12. By 15 days, 50% of animals treated with antibodies to PDL1 had completely
rejected their allografts while no grafts were rejected in the control group (Table 4). The
grafts were removed at this time for evaluation. Blockade of PDL1 caused a greater than
two- fold increase in interstitial infiltrates of CD3+ T cells and PD1expressing cells
compared to the control group (Figure 17A-E), but did not increase arterial pathology.
Double staining demonstrated that many cells co-expressed CD3 and PD1; single positive
CD3 and PD1 cells were also detected (Figure 18).

To determine whether blockade of PDL1 would modulate chronic arterial
pathology, we delayed treatment with antibody to PDL1 to days 34, 36 and 38. All the
allografts continued functioning in recipients treated either with antibody to PDL1 or
isotype controls and sacrificed at 6 weeks after transplantation. Blocking PDL1 caused
about a 2 fold increase in number of CD3 and PD1 cells in the interstitium compared to
control treated group, but the absolute numbers of cells was almost 50% lower than at 2
weeks after transplantation (Figure 17E,F). Treatment with PDL1 antibody at this later
period after transplantation did not increase vascular pathology.
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Table 4.

Cardiac allograft survival after treatment with blocking antibodies to

PDL1.

* Recipients were injected intraperitoneally with 3 doses of 200ug of purified IgG2a rat
monoclonal antibody to PDL1 (clone 10F.9G2) or 200ug of isotype control (clone LTF2) antibody (BioXCell, West Lebanon, NH) on days 8, 10 and 12 and sacrificed on day
15.

** Recipients were injected intraperitoneally with 3 doses of 200ug of purified IgG2a rat
monoclonal antibody to PDL1 (clone 10F.9G2) or 200ug of isotype control (clone LTF2) antibody (BioXCell, West Lebanon, NH) on days 34, 36 and 38 and sacrificed on day
42.
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Figure 17. Immunohistology and cell counts from mice treated with blocking antibodies
to PDL1. Administering blocking antibody to PDL1 on days 8, 10 and 12 increased
interstitial infiltrates of CD3+ T cells (B) and PD1+ (D) cells compared to controls (A and
C, respectively) at 2 weeks. Blocking PDL1 did not increase arterial pathology at 2 weeks
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(right side of panels A-D). Cell counts per 5 high power fields verified about a 2-fold
increase in CD3 and PD1 expressing cells at 2 weeks (E) and 6 weeks (F), but there was
an overall decrease in cells from 2 to 6 weeks. Each symbol in the scattergrams
represents an individual animal. All differences between control and anti-PDL-1 treated
mice were significant <0.05.

Figure 18. Immunohistology of acute interstitial infiltrates in allograft following
treatment with blocking antibodies to PDL1. Double stain for CD3 (brown) and PD1
(blue) demonstrates the majority of cells express both CD3 and PD1 (original
magnification 600x).
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2.4.6 Effect of blocking PDL1 early on mediators in the interstitial and arterial
compartments

Allografts to recipients treated with blocking antibody to PDL1 and control
recipients were microdissected for PCR analysis to determine changes associated with
accelerated rejection. Blocking PDL1:PD1 interactions caused an additional increase in
MIG, RANTES, MCP-1 and IL-1R1 as well as IL-1beta, IL-6, TNFalpha and Nos2 in the
interstitium, but not in the arterial compartment at 2 weeks (Figure 19B,C).

M2

macrophage markers were increased to a lesser extent (Figure 19D).
The chemokine expression was confirmed on the protein level by ELISA on homogenates
of control and experimental allografts. All three chemokines were upregulated by
treatment with antibodies to PDL1 (Figure 19A). However, these chemokines were more
highly expressed at 2 weeks than at 6 weeks.
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Figure 19. Treatment with blocking antibodies to PDL1 resulted in increased expression
of MIG, RANTES and MCP-1 in allografts by ELISA that was greater at 2 weeks than 6
weeks (A). These samples were taken from the apex of the hearts which contains few
large arteries. Microdissection of allografts at 2 weeks demonstrated levels of MIG,
RANTES, MCP-1, IL-1R1, IL-1beta, IL-6 TNFa and Nos2 were greater in the
interstitium than the arterial compartment (B, C). M2 macrophage markers were changed
to a lesser extent (D). Bars represent average of 3-4 samples in each group. PCR results
represent fold changes compared to allografts treated with control antibody. Differences
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between interstitial and arterial values were significant at the P<0.05*; <0.01**; or
<0.001*** level as indicated.

2.4.7 TLR4 and hyaluronan are upregulated in the arterial compartme nt during
chronic rejection

PCR array analysis showed IL1R2 and TLR4 were the most upregulated genes in
the microdissected arterial compartment in allografts compared to isografts at 2 weeks.
By 6 weeks, IL1R2 had decreased and TLR4 had dramatically increased (Table 3). This
was confirmed by qPCR analysis (Figure 20).
Among the endogenous ligands reported for TLR4 is fragmented hyaluronan, an
extracellular matrix component that is known to be upregulated in various forms of
arterial injury. Increased amounts of hyaluronan were detected by ELISA in homogenates
of allografts at 2 and 6 weeks compared to isografts (Figure 21A). Immunohistology
demonstrated increased hyaluronan in the interstitium at 2 weeks and in the neointimal
lesions and surrounding adventitial infiltrates of arteries as well as the interstitium of
cardiac allografts at 6 weeks (Figure 21B). Immunofloresence on allograft artery showed
HA expression (Figure 22A) compared to non specific control (Figure 22B). In isografts,
hyaluronan was present as a compact band in the adventitia (Figure 21C). CD44, which is
the dominant receptor for hyaluronan, was expressed by the cells infiltrating the
neointima and adventitia (Figure 23).
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Figure 20. TLR4 quantification by qPCR analysis on interstital and arterial tissue from
allografts relative to isografts at 2 and 6 weeks.
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Figure 21. Upregulation of hyaluronan in the arterial compartment at 6 weeks. ELISA
measurements of hyaluronan in allografts and isografts (A). Differences at 6 weeks were
significant P<0.01. Hyaluronan surrounded infiltrating mononuclear cells in the
neointimal lesions and adventitia of arteries as well as the interstitium of the graft (B). In
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isografts, hyaluronan formed a compact band in the adventitia of large and smaller
arteries with limited amounts in the interstitum (C). Original magnifications 200x.

Figure 22. Immunofloresence showing HA expression in allograft artery (A) and non
specific control (B).
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Figure 23. CD44, which is the dominant receptor for hyaluronan, was expressed by the
cells infiltrating the neointima and adventitia of the wild type artery (A) and SCID artery
with passive transfer of transgenic CD4 T cells (B) at 6 weeks.

2.4.8

Low molecular weight hyaluronan increases MIG and MCP-1 production

in cardiac allografts

Inflammation can cause fragmentation of hyaluronan and different sized
fragments of hyaluronan can promote or modulate chemokine production. Circulating
hyaluronan fragments have been found to stimulate chemokine production by
macrophages through a TLR4- and TLR2-dependent mechanism

24

. To test whether

hyaluronan fragments increased MIG and MCP- 1 in cardiac allografts, we administered
100ug of low molecular weight hyaluronan daily to female recipients of male allografts
intraperitoneally. Controls were administered an equal volume of the PBS diluent. Both
4.7 or 35kD fragments of hyaluronan stimulated MIG and MCP-1 production in the
cardiac allografts by 2 weeks (Figure 24A). Infiltrating cells were isolated from cardiac
transplants to mice treated with PBS or 35kD fragments of hyaluronan, and after cell
sorting for F4/80 expressing macrophages, mRNA was isolated and markers of M1 and
M2 macrophages were probed by PCR. In addition to MIG and MCP-1, the M1 markers
IL-6, IL-15, IL-18, TNFa and Nos2 were increased (Figure 24B-D).
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Figure 24. Both 4.7 or 35kD fragments of hyaluronan stimulated MIG (top left) and
MCP-1 (top right) measure by ELISA on homgenates from the apex of cardiac allografts
at 2 weeks (A). PCR on macrophages isolated from 3 heart allografts at 2 weeks
demonstrated increased expression of MIG and MCP-1 as well as even greater increases
in IL-6, IL-15, IL-18 TNF and Nos2 (B,C). Markers for M2 macrophages were
changed to a lesser extent (C). Each symbol in the ELISA scattergram represents results
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from an individual allograft. PCR results are expressed as fold increase in macrophages
from mice treated with hyaluronan fragments compared to PBS (n=3).

2.5.

Discussion

This study was designed to discover mediators that differentially modulate acute
mononuclear infiltrates in the myocardium and chronic infiltrates in the large arteries. As
in human cardiac transplants, the infiltrates in acute and chronic rejection were
predominantly composed of mononuclear cells with macrophages outnumbering T cells 1,
11

. However, the acute and chronic pathology were dependent on T cells because no

infiltrates developed in the absence of T cells, and passive transfer of CD4 T cells
restored not only the characteristic T cell infiltrates, but also the extensive macrophage
infiltrates and ultimately neointima formation with smooth muscle cells.

Macrophages are identified routinely in clinical endomyocardial biopsy by
universal macrophage markers, such as CD68

1, 11, 12

. Subpopulations of macrophages are

now recognized to have critical functional differences

10

. The most clearly defined types

of macrophages are classically activated or inflammatory M1 macrophages and
alternatively activated or wound healing M2 macrophages. Sustained production of IFNg
by T helper 1 (Th1) cells induces inflammatory macrophages during adaptive immune
responses; whereas wound healing macrophages develop in response to production of IL4 by T helper 2 (Th2) cells. No clinical or experimental studies have assessed
macrophage subpopulations in cardiac allografts, but Famulski et al 25 have reported that
M2 macrophages increase with time during T cell- mediated rejection in mouse renal
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allografts. We found relatively few Ym-1 expressing M2 macrophages in the acute
interstitial infiltrates and they increased modestly with time. Moreover, the M2
macrophages were largely ovoid without cytoplamic extensions. These histological
findings were supported by 5 molecular markers of M2 macrophages (Ym1, Fizz1,
VEGF, TGFb, and CD206), which were expressed at low levels in the interstitium and
increased at 6 weeks.

In contrast, six markers of M1 macrophages (IL-1b, IL-6, IL-15, IL-18, TNFa and
Nos2) were markedly elevated in the interstitium at 2 weeks and decreased by 6 weeks.
These changes in M1 markers paralleled the numbers and morphology of galectin-3
expressing macrophages, which had many cytoplasmic extensions that made contact with
endothelial cells and myocytes. In hearts, galectin-3 has been associated with fibrosis

22

.

Furthermore, MIG, a signature cytokine produced by inflammatory macrophages, was
elevated in interstitial samples by microarray and ELISA. MIG has been reported to colocalize with infiltrating CD68+ macrophages in clinical endomyocardial biopsies during
acute cellular rejection 12 .

In the transition to chronic rejection, galectin-3-expressing macrophages and MIG
decreased in the interstitium, and increased in the arterial compartment. In vitro, galectin3 stimulates human macrophages to upregulate inflammatory genes including RANTES
and MCP-1

23

. These 2 chemokines were upregulated acutely in the macrophage-rich

interstitium and chronically in the arterial compartment.
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In addition to increased expression of chemoattractants for macrophages and T cells,
ligands for both positive and negative co-stimulatory receptors on T cells were
upregulated in the intersititum. While CD80 and CD86 can stimulate T cells through
CD28, PDL1 delivers a negative signal to T cells that express PD1. The majority of T
cells in the interstitium expressed PD1 on immunohistology. The functional relevance of
the interaction between PDL1 and PD1 was demonstrated by treating mice with a
blocking antibody to PDL1. Blocking PDL1:PD1 interaction has been reported to
increase acute and chronic rejection of cardiac allografts in other murine models
depending upon the histoincompatibility and treatment schedule

9, 26-28

. In our model,

treatment in the acute phase caused a doubling of the number of PD1 positive cells in the
interstitium and resulted in increased tissue injury. Blocking PDL1 in the chronic phase
also increased the number of PD1 positive cells in the interstitium, but to a lesser extent
than in the acute phase. Increased infiltrates of macrophages and T cells were
accompanied by increased MIG and RANTES production in the interstitium. Yang et al
29

reported that blocking PDL1 decreased FoxP3 expressing T regulatory cells in the

spleen, but not in cardiac allografts. We also found only limited numbers of FoxP3 cells
in the interstitium or arterial compartment of cardiac allografts. Of note, blocking PDL1
changed the balance of IL-1 receptors. At 2 weeks IL-1R2 predominated in untreated
mice, but blocking PDL1 resulted in the upregulation of IL-1R1. IL-1R2 is structurally
similar to IL-1R1, but has a truncated cytoplasmic domain that prevents transmembrane
signaling

17

. IL-1R2 competes with IL-1R1 for ligands and for the IL-1 receptor

accessory protein. By acting as a decoy receptor for IL-1 on macrophages, IL-1R2
modulates the inflammatory effects of IL-1. The counterbalance between IL-1R2 and
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PD1 in our model parallels the clinical findings in the multicenter CARGO study of gene
profiles in peripheral blood mononuclear cells, which reported that IL-1R2 was the gene
most highly correlated with stable graft function and PD1 with acute rejection of cardiac
transplants

15, 16

. Our examination of graft infiltrates by flow cytometry indicated that

macrophages were equipped to modulate acute rejection because the majority expressed
PDL1.

By microdissecting tissue sections from cardiac allografts rather than homogenizing
entire samples, we examined the compartmentalization of mediators and ligands. On
microarray screen, only IL-1R2, TLR2 and 4 were more highly expressed in the arterial
than interstitial compartment in the acute phase. By 6 weeks, TLR4 increased in both
compartments, but more in arteries. TLR4 has several endogenous ligands that are
upregulated in injured arteries including galectin-3 and hyaluronan 30, 31 . The extracellular
matrix macromolecule hyaluronan has been found to increase in the hyperplastic intima
of restenotic arteries

32

. Macrophages engage in extracellular matrix remodeling both

degrading and synthesizing hyaluronan 33 . Changes in distribution of hyaluronan are not
studied routinely in clinical cardiac transplants, but have been implicated in rejection of
human lung transplants

34, 35

. Hyaluronan levels are also increased in male skin 2 weeks

after allotransplantation to female recipients

35

. Similarly, in our model, hyaluronan was

increased in homogenates of cardiac transplants at 2 and 6 weeks. In addition, we
demonstrated that increased amounts of hyaluronan were localized in the neointima of
arteries in cardiac allografts, which contained activated macrophages that could
contribute to fragmentation of the hyaluronan. Circulating hyaluronan fragments
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stimulate chemokine production by macrophages through a TLR4- and TLR2-dependent
mechanism

24

. In our model the administration of low molecular weight hyaluronan

fragments stimulated MIG and MCP-1 expression as well as M1 markers in macrophages
isolated from allografted hearts.

In summary, we found a differential expression of inflammatory signals in the
interstitial and arterial compartments of cardiac transplants that changed from the acute to
chronic phases of rejection. Our data indicate that upregulation of PDL1 in the
interstitium contributes to the resolution of acute interstitial infiltrates. In the arterial
compartment recognition of endogenous ligands including hyaluronan by TLR4 may
promote progression of arteriopathy. Importantly, our model localizes molecular markers
that have been associated with acute and chronic rejection in clinical studies of cardiac
transplants.
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CHAPTER III

CONCLUSION AND FUTURE WORK

Cardiac allograft vasculopathy (CAV) 1-2 continues to be the major cause of chronic graft
failure while advances in the treatment strategies for cardiac transplant patients have
controlled acute rejection to a large extent. The studies presented in this thesis were
designed to examine the mechanisms that are involved in the compartmentalization of
acute (localized in interstitium) and chronic (localized in large arteries) rejection. Our
results in cardiac allografts between mice mismatched at a minor histoincompatability
showed that infiltrates in acute and chronic rejection were composed of macrophages and
T cells

3,4

. These results were similar to human cardiac transplants.

Using

immunodeficient mice, we were able to show that both the acute and chronic pathology
was dependent on CD4 T-cells because no infiltrates developed in the absence of T cells,
and passive transfer of CD4 T-cells restored not only the characteristic T cell infiltrates,
but also the extensive macrophage infiltrates. Even in human cardiac transplants, CD4 Tcells have been shown to be a major component of acute and chronic infiltrates 5 .
However, these experiments did not answer why acute infiltrates were more intense in the
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interstitium than in arteries. It is known that endothelial cells activated by T cell–derived
cytokines and macrophages express class II MHC, adhesion molecules, and costimulatory molecules. These can present antigen and thereby recruit more T cells,
amplifying the rejection process. It has also been reported that activated capillary
endothelial cells express more message for leukocyte adhesion molecules than arterial
endothelial cells 6 . This greater expression of adhesion ligands by capillary endothelial
cells together with the slower blood flow in the narrow lumen of the vessels permits low
affinity interactions of lectin- like adhesion glycoproteins, called the selectins to
effectively mediate leukocyte rolling. Leukocyte rolling precedes the firm adhesion and
subsequent transendothelial migration of leukocytes mediated by the interaction of
integrins (CD11/CD18, VLA-4) on leukocytes with immunoglobulin- like adhesion
molecules on ECs (e.g., ICAM-1, VCAM-1). The importance of adhesion molecules on
capillary endothelium to early interstitial T cell infiltrates has been shown with cardiac
allografts from ICAM-1 deficient donors. Fewer T cells infiltrate these grafts at 4 days,
but these grafts still develop chronic CAV 7 .

In contrast to acute rejection, CAV is caused by infiltrates expanding in the
arterial compartment over time. The transfer of CD4 T cells to immunodeficient
recipients of cardiac grafts demonstrated that CD4 T cells caused the chronic arterial
pathology as well as the acute interstitial infiltrates.

Moreover, the numbers of

macrophages increased in these arterial lesions from 6 weeks to 10 weeks. The
proliferation marker Ki67 showed that many of the cells in the graft had recently divided.
This marker does not indicate whether the cells underwent mitosis in the arterial lesion or
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had proliferated in the lymphoid tissues and then migrated to the graft because the Ki-67
protein is present during all active phases of the cell cycle (G(1), S, G(2), and mitosis),
but is absent from resting cells (G(0))8 . However, the exact location where proliferation
was initiated remains unclear, more specifically whether cells proliferated in the graft or
in the spleen. This could be tested by performing splenectomy at different times after
transplantation. Additionally, FTY720 (fingolimod) could be used to inhibit lymphocyte
release from secondary lymphoid tissues 9

T-cells can produce cytokines that direct macrophages to differentiate into
M1 inflammatory macrophages or M2 wound healing macrophages

10

. Macrophages are

differentiated into M1 phenotype by INFg and M2 phenotype by IL-4. These M1/M2type macrophages necessarily direct T cells towards Th1- or Th2- like activities,
respectively. Macrophages initiate and direct virtually all immune responses
25).
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11

(Figure

Figure 25. Schematic showing macrophages initiate and direct virtually all immune
responses (Mill’s et al, 2014).

Our PCR and ELISA results on tissue homogenates of graft show upregulation of
chemokines, MIG (CXCL9), RANTES (CCL5) and MCP-1 (CCL2) that are involved in
the graft rejection. Manipulations of chemokines, MIG, RANTES and MCP-1 or their
receptors in the system can further elucidate the mechanisms involved in the activation,
co-stimulation, and interactions between inflammatory cells. Multiple strategies such as
using antibodies to block chemokines and their receptors or using knockout animals to
block cellular interactions could be used for future studies. MIG, RANTES and MCP-1
are interferone gamma inducible chemokines. Other possible targets indicated by our
PCR results include IL-1β that could be addressed by treatment with the soluble form of
the IL-1 decoy receptor IL-1R2 as discussed below.
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T-cells are regulated by many positive and negative co-stimulatory
signals. Our results exhibit upregulation of PD-L1, a ligand for PD-1 which is a negative
co-stimulatory molecule in the interstitium. We demonstrated functional relevance of
negative co-stimulation to the resolution of the acute interstitial infiltrate by treating mice
with a blocking antibody to PD-L1. These results indicated that early blocking of PD-L1
prevents resolution of acute interstitial infiltrates. However, it did not modulate chronic
arterial pathology. Blocking PD-L1:PD-1 interaction not only caused an additional
increase in chemokine level, IL-1R1, IL-1beta, IL-6, TNF alpha and Nos2 in the
interstitium at 2 weeks but also changed the balance of IL-1 receptors. At 2 weeks, IL1R2 predominated in untreated mice, but blocking PDL1 resulted in the upregulation of
IL-1R1. In our model, the counterbalance between IL-1R2 and PD1 parallels the clinical
findings in the multicenter CARGO study of gene profile that reported IL-1R2 is the most
highly correlated gene with the stable graft function and PD1 with acute rejection of
cardiac transplants

12, 13

. The results on graft infiltrates by flowcytometry in this work,

show that macrophages were able to modulate acute rejection because the majority
expressed IL-1R2 and PDL1. Manipulations in the IL-1 receptors in the system can
further clarify if resolution of acute interstitial infiltrate in anti PD- L1 treated group is
dependent on IL1R1.

Toll like receptors (TLRs) are a family of pattern recognition proteins that
detect both microbe and host derived molecular patterns. In our study TLR2 was
increased in the arterial more than in the interstitial compartment of cardiac allografts in
the acute phase. However, TLR4 and hyaluronan were upregulated in the arterial
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compartment during chronic rejection. Hyaluronan is one of the endogenous ligands for
TLR2 and TLR4

14

. In our model, hyaluronan was increased in tissue homogenates of

cardiac allografts at 2 and 6 weeks. This increased amount of hyaluronan was localized in
the neointimal lesions and surrounding adventitial infiltrates of arteries in cardiac
allografts. Additionally, administration of low molecular weight hyaluronan increased
MIG and MCP-1 production in cardiac allografts. We attempted to address this question
by transplanting hearts from male TLR4 knockout donors into female recipients.
However, this produced an unexpected phenotype of a dilated myocarditis

15

.

Alternatively, de la Motte and others have shown that intermediate sized fragments of
HA can deliver anti- inflammatory signals

16

. Therefore, the effects of different sizes of

HA fragments could be assessed as inhibitors of CAV.

The results presented in this thesis were obtained in a mouse model. It would be
important to translate these findings in human specimens. This is important because of
the anatomical and physiological differences between mouse and human coronary
arteries. Only a short segment of the mouse coronary is epicardial; then majority is
intramyocardial. In contrast the major branches of human coronaries that develop CAV
remain on the epicardial surface surrounded by adipose tissue. Moreover, the large
epicardial coronary arteries of humans are nourished by vasa vasorum. The absence of
vasa vasorum in the intramyocardial coronary arteries is one factor that is thought to offer
them relative protection from arteriosclerosis. The application of the panel of probes used
in the mouse model to samples from human transplants would verify markers that are
common to the development of CAV.
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Figure 26. Schematic representation of Acute Balance of Immunity between
Compartments
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Figure 27. Schematic representation of Chronic Balance of Immunity between
Compartments

The studies presented in this thesis show differential expression of
inflammatory signals in the interstitial and arterial compartments of cardiac transplants
that changed from acute to chronic phases of rejection (see Figures 26 and 27). Negative
co-stimulatory pathways are critical for the resolution of acute interstitial infiltrates. In
the arterial compartment recognition of endogenous ligands including hyaluronan by the
innate TLR4 may cause cardiac allograft vasculopathy to progress. The findings from
these and future experimental studies will further our understandings and treatments for
human cardiac allograft rejection.
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To conclude, our results show that there is acute (Figure 26) and chronic
(Figure 27) balance of immunity between interstitial and arterial compartments.
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APPENDIX

In continuation with chapter II, we have additional findings on transfer of different
numbers of Marilyn CD4 T-cells to female B6 SCID recipient of male B6 heart grafts.
These results show that the reconstitution of B6 SCID recipients of heart transplants with
CD4+ cells from Marilyn mice is dose dependent in the spleen and blood. Additionally,
the acute production of chemokines (MIG, RANTES, IP-10, MCP-1 and INFG) in the
graft caused by transferring CD4+ Marilyn T Cells is both dose and time dependent.

Hearts transplanted from male to immunodeficient fe male B6 reconstituted with
Marliyn CD4 T cells is dose and time dependent in both blood and spleen

Hearts were transplanted from wild type male B6 mice into female B6 Rag1 deficient
recipients (B6.RAG-/-), which lack mature T and B cells. One week later we
reconstituted the recipients with 5x104 , 2x104 , 2x103 , 1x103 CD4 T cells from transgenic
female B6 mice that express T-cell receptors for H-Y peptides in the context of H2-IAb
(Marilyn mice). Female B6.RAG-/- recipients were sacrificed at days 6, 7-8, 15, 16 and 4
weeks after cell transfer. The flow-cytometry results showed that reconstitution with
Marilyn CD4 T cells is dose and time dependent in blood and spleen (Figure 1).
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Figure 1. Flowcytometry analysis showing percentage of CD4 T-cells in blood and
spleen of immunodeficient recipient at different time points.

Percentage of CD4 T cells in Blood and Spleen is definitively time dependent.

Male hearts which were transplanted into female B6 Rag1 recipient reconstituted with
2x104 Marilyn CD4 T cells and sacrificed at 1, 4 and 6 weeks. The results from
flowcytometry showed that percentage of CD4 T-cells decreasing with time for a
constant dosage (Figure 2A-B). Even the splenic weight of these mice decreased with
time. These results correlated with the histology data from cardiac allografts, (refer
chapter-II), depicting intense infiltration of cells at early time point that further decreases
with time.
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Figure 2.

Flowcytometry analysis showing percentage of CD4 T cells in Blood (A)

and Spleen (B). The splenic weight (C) shows the same trend with time.
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Acute production of che mokines in the graft caused by transferring CD4+ Marilyn
T cells is time dependent.

Chemokine expression was quantitatively evaluated at protein level by ELISA on tissue
homogenates of male hearts which were transplanted into female B6 Rag1 recipient
reconstituted with 2x104 Marilyn CD4 T cells and sacrificed at 1, 4 and 6 weeks. MIG,
RANTES, MCP-1, IP-10 and INFg decreased with time with constant dosage (Figure 2).
These homogenates were prepared from the apex of the heart that contains myocardium
but no large arteries, and therefore, sampled the interstitial compartment. However,
isograft control at 1 and 6 week did not show any chemokine production.
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Figure 3. Chemokine MIG (A) RANTES (B) MCP-1 (C) IP-10 (D) & IFNg (E)
expression in cardiac allografts were quantified using ELISA on tissue homogenates of
allografts and isografts graft at 1wk ,4 wk and 6wks
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